Single B cell screening is a powerful technique for isolating and generating antigen-specific monoclonal antibodies (mAbs). This method, often integrated with high-throughput platforms, allows for efficient detection of antibody secretion and rapid identification of lead clones, thereby accelerating antibody discovery, vaccine design, and the development of targeted therapies. Single B cells are advantageous for its simplicity, as it requires only a small number of cells while maintaining a high efficiency in rapidly obtaining specific mAbs.1
The overall process is as follows:
Immunization: 1-2 months with host species with a specific antigen of interest.
Plasma B cell isolation: Collect antibody-secreting cells from spleen and bone marrow.
Single B cell screening: Protein binding and/or cell-based binding is used to detect and sort positive micro-droplets.
Single-cell sequencing.
High-throughput expression and validation.2
Biointron's high-throughput single B cell screening platform can screen 2*10^6 plasma B-cells from immunized animals. Antigen specific antibody-secreting cells can be isolated, allowing for the detection of potentially rare antibodies and drugs.
Tiller, T. (2011). Single B cell antibody technologies. New Biotechnology, 28(5), 453-457. https://doi.org/10.1016/j.nbt.2011.03.014
Pedrioli, A., & Oxenius, A. (2021). Single B Cell Technologies for monoclonal antibody discovery. Trends in Immunology, 42(12), 1143–1158. https://doi:10.1016/j.it.2021.10.008
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
